- $2.09bn
- $3.05bn
- $5.97bn
- 92
- 90
- 52
- 93
Annual income statement for Ardent Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 4,870 | 5,130 | 5,409 | 5,966 |
| Cost of Revenue | ||||
| Gross Profit | 2,576 | 2,718 | 3,025 | 3,431 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 4,487 | 4,913 | 5,185 | 5,564 |
| Operating Profit | 384 | 217 | 224 | 402 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 296 | 311 | 152 | 363 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 245 | 265 | 129 | 300 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | 154 | 189 | 53.9 | 210 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 154 | 189 | 53.9 | 210 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.307 | 0.285 | 0.331 | 1.61 |